The size of the offering was increased from the originally announced nine million shares. Incyte also granted the underwriters a 30-day option to purchase an additional 1.57 million shares of its common stock.
The company intends to use the net proceeds of this offering for general corporate purposes, including research and development activities.
Goldman, Sachs & Co is acting as the sole book-running manager of this offering and Morgan Stanley & Co is acting as the joint lead manager. JP Morgan Securities is acting as the co-manager.